A patient presented with a sudden eruption of painful, red, inflamed lesions across the face and neck—an alarming development that prompted urgent referral to dermatology. The lesions were sharply demarcated, tender to touch, and had appeared rapidly over a very short period of time, which immediately raised concern for an acute inflammatory, infectious, or immune-mediated process rather than a chronic dermatologic condition. The distribution, morphology, and speed of onset were particularly concerning, as they suggested a systemic trigger rather than a localized skin disorder.
Given the patient’s recent medication history, clinicians initially suspected a possible drug-related reaction. Drug-induced eruptions are among the most common causes of acute widespread cutaneous inflammation, and the temporal relationship between medication exposure and symptom onset further strengthened this suspicion. As a precautionary measure, the suspected agent was promptly discontinued. In many clinical scenarios, early withdrawal of a potential offending drug is both diagnostic and therapeutic, helping prevent progression of symptoms while further investigations are underway.
The initial clinical evaluation triggered a comprehensive diagnostic workup aimed at narrowing the differential diagnosis. A skin biopsy was performed to evaluate histopathological features, as biopsy remains a cornerstone in distinguishing between overlapping inflammatory dermatoses. In parallel, laboratory investigations were initiated, including a complete blood count to assess for leukocytosis or cytopenias, inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate, and an extended immunological panel. Autoimmune screening was also included, with testing for antinuclear antibodies, anti-double-stranded DNA, extractable nuclear antigens, and lupus anticoagulant. These tests were ordered to rule out systemic autoimmune diseases or connective tissue disorders that can present with cutaneous manifestations.
While awaiting results, empirical treatment was started with systemic corticosteroids. This decision was based on the severity of the inflammation, the patient’s discomfort, and the need for rapid symptom control. Corticosteroids are often used in dermatologic emergencies where immune-mediated inflammation is suspected, as they exert broad anti-inflammatory effects by suppressing cytokine production and neutrophil activation. The clinical response was both rapid and striking. Within 48 hours of initiating therapy, the patient experienced significant improvement. Pain diminished considerably, erythema began to fade, and the lesions showed early signs of resolution. This dramatic response provided an early clinical clue pointing toward a steroid-responsive inflammatory dermatosis.
Laboratory results further contributed to the evolving clinical picture. The complete blood count revealed leukocytosis with marked neutrophilia, indicating an acute inflammatory response dominated by neutrophils rather than lymphocytes. This pattern is often seen in bacterial infections, drug reactions, and neutrophilic dermatoses. Inflammatory markers were elevated, consistent with systemic inflammation. Immunological testing yielded mixed findings: the presence of positive antibodies and lupus anticoagulant was noted, but routine serological markers typically associated with systemic autoimmune disease were otherwise negative. While these findings were noteworthy, they were not sufficient on their own to establish a definitive diagnosis and required correlation with clinical and histological data.
The turning point in the diagnostic process came with the histopathological analysis of the skin biopsy. Microscopic examination revealed a dense dermal infiltrate composed predominantly of mature neutrophils, situated primarily in the upper dermis. Importantly, there was no evidence of leukocytoclastic vasculitis, which helped exclude several other inflammatory conditions. The epidermis was largely spared, and there was associated dermal edema. These histological features were characteristic of Sweet syndrome, also known as acute febrile neutrophilic dermatosis.
Sweet syndrome is a rare but well-recognized inflammatory condition characterized by the abrupt onset of painful erythematous papules, plaques, or nodules. Although fever is commonly associated with the condition, it may not always be present. The syndrome is defined histologically by a dense infiltration of neutrophils in the upper dermis without evidence of vasculitis. It can affect a wide range of organs beyond the skin in some cases, reflecting its systemic inflammatory nature.
The exact pathogenesis of Sweet syndrome remains incompletely understood, but it is widely believed to involve dysregulation of the immune system, particularly cytokine-mediated activation and recruitment of neutrophils. Elevated levels of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and granulocyte colony-stimulating factor have been implicated in its development. The condition is thought to represent a hypersensitivity reaction in many cases, triggered by a variety of internal or external stimuli.
Sweet syndrome has been associated with multiple underlying conditions. These include infections, inflammatory diseases, and malignancies—particularly hematologic cancers such as acute myeloid leukemia. It can also occur in association with solid tumors, autoimmune disorders, and pregnancy. Importantly, drug-induced Sweet syndrome represents a significant subset of cases. Medications implicated include antibiotics, antiepileptic drugs, oral contraceptives, antihypertensives, vaccines, and hematopoietic growth factors such as granulocyte colony-stimulating factor. In drug-induced cases, withdrawal of the offending agent is essential and often leads to rapid improvement.
In the present case, the combination of abrupt symptom onset, neutrophilic leukocytosis, steroid responsiveness, and characteristic biopsy findings strongly supported the diagnosis of Sweet syndrome. The presence of lupus anticoagulant and positive antibodies introduced additional complexity, raising consideration of an underlying immune dysregulation, although no definitive systemic autoimmune disease was confirmed at the time of evaluation. Such findings sometimes occur transiently in inflammatory states and require follow-up to determine persistence or clinical significance.
The differential diagnosis for this presentation was broad and included several important dermatologic and systemic conditions. Urticaria was considered, but the lesions in urticaria are typically transient, non-tender, and not associated with dermal neutrophilic infiltration. Allergic or irritant contact dermatitis was also considered, but the sharply demarcated, rapidly progressing, and painful nature of the lesions was not typical. Drug eruptions, including morbilliform drug exanthema or more severe toxidermias, were evaluated, but histology and clinical course did not support these diagnoses. Autoimmune conditions such as systemic lupus erythematosus were also part of the differential, particularly given the serological findings, but the absence of characteristic clinical and laboratory features made this less likely.
Infectious causes were also carefully excluded, as bacterial cellulitis or deep skin infections can present with erythema, pain, and systemic inflammatory markers. However, the distribution, multiplicity of lesions, and biopsy findings were not consistent with an infectious process. The lack of organisms on histological examination further supported a sterile inflammatory etiology.
Management of Sweet syndrome primarily involves systemic corticosteroids, which are considered first-line therapy. The rapid response observed in this patient is typical and often serves as both a therapeutic and diagnostic confirmation. In cases where corticosteroids are contraindicated or ineffective, alternative therapies such as colchicine, dapsone, potassium iodide, or immunosuppressive agents may be considered. Treatment duration is typically tapered gradually to prevent recurrence, as abrupt discontinuation may lead to relapse.
Equally important in management is the identification and treatment of any underlying cause. If Sweet syndrome is secondary to infection, malignancy, or medication exposure, addressing the root trigger is essential for long-term control. In this case, discontinuation of the suspected drug was already initiated, and further monitoring was recommended to evaluate for recurrence or systemic disease development.
Follow-up care plays a critical role in patient management. Even when initial symptoms resolve, patients require ongoing observation to monitor for recurrence and to reassess for any evolving systemic conditions, particularly hematologic malignancies that may initially present subtly. Repeat laboratory testing and clinical evaluations are often necessary over time.
This case underscores several key clinical principles. First, it highlights the importance of recognizing the pattern of acute, painful, neutrophil-rich skin lesions as a potential indicator of Sweet syndrome. Second, it demonstrates the value of early biopsy in establishing a definitive diagnosis in dermatologic conditions with broad differentials. Third, it emphasizes the importance of considering drug-induced etiologies in acute inflammatory presentations and acting promptly to discontinue suspected agents. Finally, it illustrates how cutaneous findings can serve as a window into systemic disease processes, sometimes preceding or revealing deeper underlying pathology.
Ultimately, Sweet syndrome represents a striking example of the intersection between dermatology and systemic immunology. While the skin manifestations are often dramatic and distressing, they are usually highly responsive to treatment. However, the condition should never be viewed in isolation, as it may signal broader systemic involvement. Careful diagnostic evaluation, prompt treatment, and vigilant follow-up are essential components of optimal patient care in such cases.
